Suppr超能文献

子宫肌瘤患者行子宫肌瘤剔除术、子宫内膜消融术和子宫动脉栓塞术后的再干预率。

Reintervention Rates After Myomectomy, Endometrial Ablation, and Uterine Artery Embolization for Patients with Uterine Fibroids.

机构信息

1 Medicus Economics , Milton, Massachusetts.

2 AbbVie, Inc. , North Chicago, Illinois.

出版信息

J Womens Health (Larchmt). 2018 Oct;27(10):1204-1214. doi: 10.1089/jwh.2017.6752. Epub 2018 Aug 7.

Abstract

BACKGROUND

Women with uterine fibroids (UF) may undergo less invasive procedures than hysterectomy, including myomectomy, endometrial ablation (EA), and uterine artery embolization (UAE); however, long-term need for reintervention is not well characterized. We estimated reintervention rates for 5 years and identified predictors of reintervention.

MATERIALS AND METHODS

A longitudinal retrospective cohort study was conducted in women in MarketScan Commercial Claims and Encounters (Truven Health Analytics) aged 18-49 years with UF diagnosis before myomectomy, EA, or UAE from 2008 to 2014. Patients were categorized by initial procedure (index date) and required to have ≥12 months of continuous coverage before and after. Kaplan-Meier analyses and Cox proportional hazard models were used to estimate survival without reintervention and hazard of reintervention for 5 years.

RESULTS

The study included 35,631 women with myomectomy (n = 13,804: 8,018 abdominal, 941 hysteroscopic, and 4,845 laparoscopic), EA (n = 17,198), and UAE (n = 4,629). Myomectomy had the lowest 12-month reintervention rate (4.2%), followed by UAE (7.0%), then EA (12.4%; both p < 0.001 relative of myomectomy). Estimates of 5-year reintervention rates were 19% for myomectomy (17%, 28%, and 20% for abdominal, hysteroscopic, and laparoscopic, respectively), 33% for EA, and 24% for UAE. EA and UAE had adjusted hazard ratios of 2.63 (95% confidence interval [CI], 2.44-2.83) and 1.56 (95% CI, 1.42-1.72). Prior anemia, bleeding, pelvic inflammatory disease, and abdominal and pelvic pain increased the hazard of reintervention.

CONCLUSION

Reintervention rate estimates ranged from 17% to 33% for 5 years after myomectomy, EA, and UAE for patients with UF. Risk of requiring reintervention should be considered during treatment selection.

摘要

背景

患有子宫肌瘤(UF)的女性可能会接受比子宫切除术创伤更小的治疗,包括子宫肌瘤切除术、子宫内膜消融术(EA)和子宫动脉栓塞术(UAE);然而,长期需要再次干预的情况尚未得到很好的描述。我们评估了 5 年内的再次干预率,并确定了再次干预的预测因素。

材料和方法

在 MarketScan 商业索赔和就诊记录(Truven Health Analytics)中,进行了一项纵向回顾性队列研究,该研究纳入了 2008 年至 2014 年间年龄在 18 至 49 岁之间、接受过子宫肌瘤切除术、EA 或 UAE 治疗的 UF 患者。根据初始治疗(索引日期)将患者分类,并要求在治疗前后至少有 12 个月的连续覆盖。使用 Kaplan-Meier 分析和 Cox 比例风险模型来估计 5 年内无需再次干预的生存率和再次干预的风险。

结果

研究纳入了 35631 名接受子宫肌瘤切除术(n=13804:8018 例剖腹、941 例宫腔镜和 4845 例腹腔镜)、EA(n=17198)和 UAE(n=4629)治疗的女性。子宫肌瘤切除术的 12 个月再次干预率最低(4.2%),其次是 UAE(7.0%),其次是 EA(12.4%;与子宫肌瘤切除术相比均 P<0.001)。子宫肌瘤切除术、EA 和 UAE 的 5 年再次干预率估计值分别为 19%(17%、28%和 20%,分别为剖腹、宫腔镜和腹腔镜)、33%和 24%。EA 和 UAE 的调整后风险比分别为 2.63(95%置信区间[CI],2.44-2.83)和 1.56(95%CI,1.42-1.72)。先前存在的贫血、出血、盆腔炎以及腹部和盆腔疼痛会增加再次干预的风险。

结论

对于 UF 患者,接受子宫肌瘤切除术、EA 和 UAE 治疗后的 5 年内,再次干预率估计值在 17%至 33%之间。在治疗选择时应考虑需要再次干预的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ecf/6205049/b559f6a0f37f/fig-1.jpg

相似文献

1
Reintervention Rates After Myomectomy, Endometrial Ablation, and Uterine Artery Embolization for Patients with Uterine Fibroids.
J Womens Health (Larchmt). 2018 Oct;27(10):1204-1214. doi: 10.1089/jwh.2017.6752. Epub 2018 Aug 7.
2
Comparative Effectiveness of Uterine Leiomyoma Procedures Using a Large Insurance Claims Database.
Obstet Gynecol. 2017 Nov;130(5):1047-1056. doi: 10.1097/AOG.0000000000002331.
4
Long-Term Risk of Reintervention After Surgical Leiomyoma Treatment in an Integrated Health Care System.
Obstet Gynecol. 2024 May 1;143(5):619-626. doi: 10.1097/AOG.0000000000005557. Epub 2024 Mar 28.
5
Non-extirpative Treatments for Uterine Myomas: Measuring Success.
J Minim Invasive Gynecol. 2021 Mar;28(3):442-452.e4. doi: 10.1016/j.jmig.2020.08.016. Epub 2020 Aug 22.
6
Uterine-Artery Embolization or Myomectomy for Uterine Fibroids.
N Engl J Med. 2020 Jul 30;383(5):440-451. doi: 10.1056/NEJMoa1914735.
7
Uterine artery embolization for symptomatic uterine fibroids.
Cochrane Database Syst Rev. 2012 May 16(5):CD005073. doi: 10.1002/14651858.CD005073.pub3.
8
Pre-operative uterine artery embolization before hysterectomy or myomectomy: a single-center review of 53 patients.
Clin Imaging. 2023 Sep;101:121-125. doi: 10.1016/j.clinimag.2023.06.003. Epub 2023 Jun 9.

引用本文的文献

1
Uterine fibroid embolization: An analysis of clinical outcomes and impact on patients' quality of life.
Open Med (Wars). 2025 Aug 7;20(1):20251235. doi: 10.1515/med-2025-1235. eCollection 2025.
2
Uterine Artery Embolization: A Growing Pillar of Gynecological Intervention.
J Radiol Clin Imaging. 2025;8(1):1-17. doi: 10.26502/jrci.2809105. Epub 2025 Feb 4.
3
Polyethylene Glycol microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids.
Radiol Med. 2025 Mar;130(3):315-326. doi: 10.1007/s11547-025-01955-7. Epub 2025 Jan 20.
4
Risk Factors of Complications After Uterine Artery Embolisation for Symptomatic Fibroids: A Case-Control Study.
BJOG. 2025 Mar;132(4):518-528. doi: 10.1111/1471-0528.18023. Epub 2024 Dec 1.
5
Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial.
PLoS One. 2024 Jul 2;19(7):e0306053. doi: 10.1371/journal.pone.0306053. eCollection 2024.
6
Uterine artery embolization versus myomectomy: a systematic review and meta-analysis.
SAGE Open Med. 2024 May 14;12:20503121241236141. doi: 10.1177/20503121241236141. eCollection 2024.
7
Long-Term Risk of Reintervention After Surgical Leiomyoma Treatment in an Integrated Health Care System.
Obstet Gynecol. 2024 May 1;143(5):619-626. doi: 10.1097/AOG.0000000000005557. Epub 2024 Mar 28.
9
Updates on the Surgical Approach to Fibroids: The Importance of Radiofrequency Ablation.
Semin Intervent Radiol. 2023 Aug 10;40(4):335-341. doi: 10.1055/s-0043-1770734. eCollection 2023 Aug.

本文引用的文献

1
Comparative Effectiveness of Uterine Leiomyoma Procedures Using a Large Insurance Claims Database.
Obstet Gynecol. 2017 Nov;130(5):1047-1056. doi: 10.1097/AOG.0000000000002331.
2
Analysis of subsequent surgery rates among endometriosis patients who underwent surgery with and without concomitant leuprolide acetate therapy.
Curr Med Res Opin. 2016 Jun;32(6):1073-82. doi: 10.1185/03007995.2016.1159189. Epub 2016 Mar 30.
3
Association Between Patient Characteristics and Treatment Procedure Among Patients With Uterine Leiomyomas.
Obstet Gynecol. 2016 Jan;127(1):67-77. doi: 10.1097/AOG.0000000000001160.
4
The incidence of hysterectomy, uterus-preserving procedures and recurrent treatment in the management of uterine fibroids.
Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:147-52. doi: 10.1016/j.ejogrb.2015.08.034. Epub 2015 Sep 1.
6
The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013.
Am J Obstet Gynecol. 2015 Aug;213(2):141-60. doi: 10.1016/j.ajog.2015.03.019. Epub 2015 Mar 11.
7
The management of uterine leiomyomas.
J Obstet Gynaecol Can. 2015 Feb;37(2):157-178. doi: 10.1016/S1701-2163(15)30338-8.
8
Cost comparison between uterine-sparing fibroid treatments one year following treatment.
J Ther Ultrasound. 2014 Mar 31;2:7. doi: 10.1186/2050-5736-2-7. eCollection 2014.
10
Minimally invasive surgical techniques versus open myomectomy for uterine fibroids.
Cochrane Database Syst Rev. 2014 Oct 21;2014(10):CD004638. doi: 10.1002/14651858.CD004638.pub3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验